News and Gossips

Diabetes Drug Reduces Risk of Heart Disease in Trial To find The solutions

on

Diabetes is a chronic, often debilitating and
sometimes fatal disease, in which the body either
cannot produce 1nsul1n or cannot properly use
the 1nsul1n it produces.

Dulaglutide (Trulicity), Eli Lilly’s treatment for type 2 diabetes,
significantly reduced the risk of heart attack, stroke,

Heart-related death in individuals with diabetes, drugs Reuters
reported.

According to the article, Eli Lilly said dulaglutide is
the first type 2 diabetes drug to show this kind of statistically
significant reduction in heart risk during a clinical trial in
which a majority of patients did not already have heart disease.

The trial compared 1.5 mg of dulaglutide once per
week with a placebo in 9901 patients, the article reported.

Eli Lilly said it will disclose the full results of the trial at the
American Diabetes Association meeting in June and plans to
submit data to regulators for review next year.

A recent US Drug Enforcement Administration report showed
that drug overdose deaths have hit the highest level ever
recorded in the United States last year, the Associated Press
reported.

According to the article, preliminary figures show
more than 72,000 individuals died from drug overdoses
across the United States in 2017, with 46,060 being opioid-
related deaths.

The report showed that heroin, fentanyl, and
other opioids continue to present the highest overdose threat,
the article reported.

Novartis’ Sandoz division will not proceed with efforts to gain
FDA approval for its biosimilar of rituximab, a drug used to
treat certain types of cancer and rheumatoid arthritis, Reuters reported.

According to the article, Novartis decided to
abandon efforts after the agency sought additional
information to support the company’s application for the drug,
which is already approved in the European Union, Switzerland,Japan, and Australia.
Japan, and Australia.

Sandoz received a complete response
letter from the FDA for biosimilar rituximab on May 2, the
article reported

About Kelvin Onyekachi

Leave a Reply

Your email address will not be published. Required fields are marked *